CAPR · CIK 0001133869
What Capricor Therapeutics, Inc. told the SEC could break it.
Capricor's risks cluster on a fragile, concentrated manufacturing base for its cell therapy. Some specialized raw materials used in its allogeneic CDC manufacturing are available only from one or a limited number of suppliers, and certain product components are single-sourced, so the loss of a supplier could significantly disrupt the business. That risk is compounded geographically: its headquarters and both Deramiocel manufacturing and research facilities sit in San Diego and the Los Angeles area, a region prone to earthquakes, drought and fires, so a natural disaster could hit its sole manufacturing footprint. Looking ahead, any approved product would face drug-pricing pressure from the Inflation Reduction Act — inflation rebates, the $2,000 Part D out-of-pocket cap with new manufacturer discounts, and Medicare 'maximum fair price' negotiation.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- specialized cell-therapy raw materials from single/limited suppliershigh
Some specialized raw materials used in Capricor's cell-therapy (allogeneic CDC) manufacturing are available only from one or a limited number of suppliers, and certain product components are single-sourced; loss of a material supplier could significantly disrupt its business.
“Some specialized raw materials used in cell therapy manufacturing may be available only from one or a limited number of suppliers. In some cases, we obtain components used in certain of our products from single sources.”
SEC filing →As of 2026
Geographic concentration
- California (San Diego + Los Angeles) manufacturingmedium
Capricor's headquarters and its two Deramiocel manufacturing/research facilities are concentrated in San Diego and the Los Angeles, California area — a region prone to seismic activity, drought and fires — so a natural disaster there could disrupt its sole manufacturing base.
“Our corporate headquarters and our manufacturing and research facilities are located in San Diego and in the Los Angeles, California area, a region known for seismic activity, as well as being susceptible to drought and fires.”
Regulatory & policy
- Inflation Reduction Act drug-pricing reformsmedium
The Inflation Reduction Act's drug-pricing reforms — inflation rebates on Medicare Part B/D products that outpace inflation, the $2,000 Part D out-of-pocket cap with new manufacturer discount obligations, and the Medicare 'maximum fair price' negotiation — could constrain pricing and reimbursement for Capricor's Deramiocel if approved.
“the IRA imposes inflation rebates on drug and biological product manufacturers for products reimbursed under Medicare Parts B and D if the prices of those products increase faster than inflation; implements changes to the Medicare Part D benefit that cap beneficiary annual out-of-pocket spending at $2,000 (adjusted annually for inflation), with new discount obligations for pharmaceutical manufacturers”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Nippon Shinyaku Co., Ltd.
“We will depend on our exclusive distributor, Nippon Shinyaku, for the commercial sale of Deramiocel in Duchenne muscular dystrophy (“DMD”) in the United States and Japan, if regulatory approval is obtained in those territories.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch